Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified October 2014 by Lipella Pharmaceuticals, Inc.
Sponsor:
Collaborator:
William Beaumont Hospitals
Information provided by (Responsible Party):
Lipella Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01393223
First received: July 7, 2011
Last updated: October 23, 2014
Last verified: October 2014

July 7, 2011
October 23, 2014
February 2015
June 2016   (final data collection date for primary outcome measure)
Safety [ Time Frame: Up to 31 weeks following treatment ] [ Designated as safety issue: Yes ]
The number/severity of adverse events throughout the study
Same as current
Complete list of historical versions of study NCT01393223 on ClinicalTrials.gov Archive Site
  • Efficacy Voids Per Day (VPD) [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change in voids per day (urinary frequency) as measured on a 3 day voiding diary
  • Efficacy Global Response Assessment (GRA) [ Time Frame: 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    Reporting a "moderate" or "marked" improvement on the GRA
  • Efficacy Symptom [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change in the symptoms and problems of interstitial cystitis from the baseline as measured by the O'Leary-Sant Interstitial Cystitis Symptom Index
  • Efficacy Visual Analog Scale (VAS) [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change in pain as recorded on the VAS
  • Efficacy Diary [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change from baseline in average voided volume, urgency and nocturia episodes per day as measured on a 3 day voiding diary
  • Efficacy VPD [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change in voids per day (urinary frequency) as measured on a 3 day voiding diary
  • Efficacy GRA [ Time Frame: 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    Reporting a "moderate" or "marked" improvement on the GRA
  • Efficacy Symptom [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change in the symptoms and problems of IC from the baseline as measured by the O'Leary-Sant Interstitial Cystitis Symptom Index
  • Efficacy VAS [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change in pain as recorded on the Visual Analog Scale (VAS)
  • Efficacy Diary [ Time Frame: 2, 4, 8, 16, 24 weeks following treatment ] [ Designated as safety issue: No ]
    The change from baseline in average voided volume, urgency and nocturia episodes per day as measured on a 3 day voiding diary
Not Provided
Not Provided
 
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

The purpose of this study is to assess the safety and tolerability of two doses of LP08 compared to placebo. Hypothesis: Safety of the LP-08 therapy will not be significantly different from the placebo group. Secondary Efficacy Endpoints: A matched-pair data analysis design will be employed, i.e. the measured outcomes will be subjects' improvements in quantitative and qualitative measures of the disease condition being assessed prior to and after LP-08 instillations at four and eight weeks follow-up visits

This is a single-center, dose-ranging, placebo-controlled, double-blind, randomized study including male and female subjects with interstitial cystitis/bladder pain syndrome (IC/BPS) as determined by a physician using the current diagnostic criteria for IC/BPS. A total of 36 subjects will be enrolled at up to five (5) study sites in the U.S. Enrollment is expected to be completed within one year of initiating the study. The study is comprised of two parts. The first part of the study is a dose-ranging, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of LP-08 at 20 mg and 80 mg doses as compared with placebo. The second part of the study is an Open Label Extension study of the safety, tolerability and efficacy of LP-08 80 mg. Subjects randomized to the placebo control group must have completed the randomized portion study, including the eight week follow-up period, to be eligible for the Open Label Extension.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Interstitial Cystitis
  • Drug: LP-08 80mg
  • Drug: Normal Saline Placebo
  • Drug: LP-08 20mg
  • Active Comparator: LP-08 80mg
    4 weekly intravesical administration of LP-08 80mg
    Intervention: Drug: LP-08 80mg
  • Active Comparator: LP-08 20mg
    4 weekly intravesical administration of LP-08 20mg
    Intervention: Drug: LP-08 20mg
  • Placebo Comparator: Normal Saline
    Four weekly normal saline intravesical administration
    Intervention: Drug: Normal Saline Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
36
July 2016
June 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

A patient is deemed suitable for inclusion in the study if the patient meets the following criteria:

  1. Male or female at least 18 years of age
  2. IC/BPS diagnosed by a health care provider based the following criteria:

    Complaint of suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and night time frequency, in the absence of proven urinary infection or other obvious pathology Have had IC/BPS symptoms for at least six months Score of ≥ 12 on the ICSI/PI at baseline Urinary frequency > 10 times a day by self-report and confirmed on baseline three-day voiding diary Have IC/BPS that in the judgment of the investigator has been stable in the previous 30 days IC/BPS-related pain defined as a score of > 3 cm and < 9 cm on the pain VAS where 0 is no pain and 10 is maximum pain

  3. Have had inadequate clinical responses with conservative treatments, which may include one or more of the following: 1) timed voiding and behavioral modification therapy, 2) dietary restrictions, 3) stress reduction and/or 5) oral therapy with any of the following medications:

    Antidepressants Antihistamines Antimuscarinic and anticholinergic agents Alpha adrenergic blockers Analgesics Pentosan polysulfate

  4. Have at least one voided volume > 75 mL in a 24-hour period
  5. Women of childbearing potential: have a negative urine pregnancy test at screening, and must agree to use an acceptable from of contraception (oral contraceptives, intrauterine or double barrier methods), as agreed to by the investigator, during the study period
  6. Provide signed informed consent
  7. Subject agrees to be available for the follow-up evaluations as required by the protocol

Exclusion Criteria:

Patients are excluded from enrollment in the study if any of the following are true:

  1. Currently pregnant or breastfeeding, or plan to become pregnant during the course of the study
  2. Have received investigational products or devices within 30 days prior to screening visit
  3. Have had symptoms of IC/BPS for more than 10 years
  4. Have received intravesical therapy or bladder hydrodistention within 30 days prior to screening visit. Intravesical instillations may include liquid or drug delivery devices, pentosan polysulfate sodium, lidocaine, steroid, heparin, chondroitin and any combination or additional formulation.
  5. Have participated in IC/BPS research trial within 90 days prior to screening visit or has not returned to baseline if participated in IC/BPS research trial greater than 90 days prior to screening visit
  6. Have received any of the following medication within 30 days of screening visit, unless such medications have been administered at a stable dose during this month and are expected to remain at a stable dose throughout the study:

    Antidepressants Antihistamines (use of antihistamines as needed for allergies is allowed) Anticonvulsants Antimuscarinic and anticholinergic agents Alpha adrenergic blockers Pentosan polysulfate sodium Oral chondroitin

  7. Have indicated use of > 70 mg of morphine equivalents of opioids per week to control their IC/BPS pain within 30 days prior to screening, or are expected to require this level of IC/BPS pain control during the study period
  8. Previous augmentation cystoplasty, cystectomy, neurectomy (i.e., hypogastric nerve plexus ablation) or bladder botulinum toxin injections
  9. Sacral and/or pudendal nerve neuromodulation device (Interstim) within the last 6 months. Subjects would not be excluded if they had Interstim greater than 6 months ago and is on a stable setting within the past 90 days
  10. Percutaneous Tibial Nerve Stimulation (PTNS) treatment within the past 90 days
  11. Evidence of renal impairment (creatinine > two times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > three times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment
  12. Post-void residual (PVR) urine volume of > 150 mL at screening
  13. Any condition that in the judgment of the investigator would interfere with the patient's ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which might confound the interpretation of the study results
  14. Previously received intravesical liposomes
  15. Urinary tract or prostatic infection in the past 90 days before study entry
  16. Active genital herpes or vaginitis
  17. Urethral diverticulum
  18. Pelvic malignancy within the past five years
  19. History of cyclophosphamide or chemical cystitis, or tuberculosis or pelvic radiation
  20. History of bladder or prostate tumors (benign or malignant)
  21. Uncontrolled diabetes
  22. Has any condition that would preclude treatment due to contraindications and/or warnings in the product labeling
Both
18 Years to 70 Years
No
Contact: Jonathan Kafuman, PhD 412-894-1853 jhk@lipella.com
Contact: Michele A Gruber, BS 412-894-1853 michele.anthony@lipella.com
United States
 
NCT01393223
PhaseII LP-08 IC/BPS
Yes
Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc.
William Beaumont Hospitals
Not Provided
Lipella Pharmaceuticals, Inc.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP